KPRX 株価分析 — Kiora Pharmaceuticals Inc (Healthcare >> Biotechnology)
KPRX に関するよくある質問
KPRXのPER(株価収益率)は?
Kiora Pharmaceuticals Inc(KPRX)は現在PER 408.37倍で取引されています。
KPRXのROE(自己資本利益率)は?
Kiora Pharmaceuticals IncのROEは-79.37%です。
KPRXの配当利回りは?
Kiora Pharmaceuticals Incの配当利回りは0.00%です。
KPRXの品質スコア(Quality Score)は?
当社のAIはKPRXの総合財務品質を100点中8点と評価しています。収益性・成長性・負債・利益の安定性に基づく評価です。
KPRXは今が買い時ですか?
当社AIのタイミングスコアは100点中4点で、テクニカル指標とモメンタムから見た現在価格の相対的な魅力度を示します。
KPRXはどのセクターに属しますか?
Kiora Pharmaceuticals IncはHealthcare >> Biotechnologyセクターに分類されます(NASDAQ市場)
KPRX AI Analysis Summary
Our AI summary for KPRX: Kiora Pharmaceuticals Inc (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 408.37, ROE of -79.37%, a dividend yield of 0.00%. Its financial Quality Score stands at 8/100 — fundamentals below the market average. The AI Timing Score is 4/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 2.54
Price
0.07
(2.83%)
Day Change
|
|
|---|
KPRX, ファンダメンタルスコアはnot good ( ファンダメンタル = 8) そして テクニカルスコアは ...(Sign In to See)...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
P/Eが高い。割高銘柄。
ROEが低い
ROAが低い
ROEの伸びが低い
平均ROEが低い
昨年度のROEが一昨年比で低い
ROEが昨年度比で低い
ROAがROEに比べて低い
ROAの伸びが低い
Last-year ROA is lower than last-2-years ROA.
昨年度のROAが一昨年比で低い
NPMが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not good , and ability to make profit is not quite good , ...
| Deepscope 分析 |
|
42% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | N/A |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 2.54 |
| PBV / Sector |
0.79 / 44,105.10
GREAT
|
| Earning Per Share | -2.57 |
| PE / Sector |
408.37 / 19.37
|
| PEG or PE/Growth / Sector |
-2.55 / 1.06
|
| Average 1M Daily Value |
0.06 M
GREAT
|
| Average 1W Daily Value |
0.04 M
GREAT
|
| Timing Factors |
|
28% |
| Financial Health |
|
45% |
| ポイントになる統計 |
|
56% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-08-06 08:00:15 |
| Symbol | KPRX |
| Name | KIORA PHARMACEUTICALS INC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 4.43 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 10.95 / 9,702.21 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 332 Encinitas Boulevard, Encinitas, CA, United States, 92024
Phone: 858 224 9600
Website: https://www.kiorapharma.com
Sector: Healthcare >> Biotechnology
Description: Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of ophthalmic diseases. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 2 clinical trials for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. The company is also developing KIO-104, a non-steroidal, immuno-modulatory, small-molecule inhibitor of dihydroorotate dehydrogenase, which is in phase 1b/2a study for the treatment of posterior non-infectious uveitis, as well as under pre-clinical development for the treatment of proliferative vitreoretinopathy; and KIO-101, an eye drop formulation for the treatment of ocular presentation of rheumatoid arthritis. It has a strategic development and commercialization agreement with Théa Open Innovation for the development of KIO-301. The company operates in the United States, Austria, and Australia. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Encinitas, California.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
Google